ImCheck Therapeutics is designing and developing a new generation of immunotherapy antibodies positioned at the crossroads of two high-potential immunological fields: γ9δ2 T cells and a novel super-family of immunomodulators, butyrophilins.
Due to their mechanism of action, and notably their ability to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior anti-cancer efficacy as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, overcome the resistance to this class of agents. Activated γ9δ2 T cells also have therapeutic potential in infectious diseases (e.g., bacteria and viruses), while antagonist antibodies have potential as treatments for a range of autoimmune diseases.
Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.
Location: France, Provence-Alpes-Côte d'Azur, Marseille
Employees: 11-50
Total raised: $175.37M
Founded date: 2015
Investors 7
Funding Rounds 3
Date | Series | Amount | Investors |
14.06.2022 | - | $100.5M | - |
04.12.2019 | Series B | $53M | - |
02.05.2017 | Series A | $21.87M | - |
Mentions in press and media 16
Date | Title | Description | Source |
17.07.2023 | Earlybird Health's Inaugural Impact & ESG report reveals... | Whether you like it or not, you'll be hearing a lot about ESG (Environmental Social Governance) metr... | tech.eu/20... |
13.06.2022 | ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Fina... | Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, ... | globenewsw... |
13.06.2022 | With stacked to-do list, ImCheck checks off next funding rou... | A phase 2 trial ready to expand? Check. Plans for combination studies? Check. More pipeline assets t... | fiercebiot... |
13.06.2022 | ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Fina... | ImCheck Therapeutics announced today the close of a EUR 96 million (USD 103 million) financing, co-l... | anderapart... |
21.10.2021 | ImCheck Publishes Comprehensive Overview of the Development ... | ImCheck Therapeutics announced the publication of the preclinical to clinical development of its lea... | wellington... |
17.09.2021 | ImCheck Presents Preliminary Patient Response Data from the ... | ImCheck Therapeutics today presented data at the ESMO Congress 2021 from its ongoing EVICTION Phase ... | wellington... |
09.04.2021 | Clinical Data with ImCheck’s ICT01 to be Presented at AACR: ... | ICT01 activates γ9δ2 T cells that rapidly migrate out of the circulation and secrete IFNγ and TNFα l... | wellington... |
15.09.2020 | ImCheck Announces Investment by BB Pureos Bioventures to Clo... | ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €5... | marketscre... |
15.09.2020 | GIMV NV Gimv : ImCheck Announces Investment by BB Pureos Bi... | Marseille, France, September 15, 2020 - ImCheck Therapeutics today announced that it has secured an ... | marketscre... |
26.03.2020 | First patient dosed in EVICTION trial evaluating ImCheck’s l... | ImCheck Therapeutics has dosed the first patient in a Phase I/IIa clinical trial evaluating ICT01, a... | wellington... |
Show more